Reverse Transcriptase Inhibitors
"Reverse Transcriptase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template.
| Descriptor ID |
D018894
|
| MeSH Number(s) |
D27.505.519.389.675.850 D27.505.954.122.388.077.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Reverse Transcriptase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Reverse Transcriptase Inhibitors".
This graph shows the total number of publications written about "Reverse Transcriptase Inhibitors" by people in this website by year, and whether "Reverse Transcriptase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 2000 | 2 | 0 | 2 |
| 2003 | 0 | 1 | 1 |
| 2005 | 1 | 0 | 1 |
| 2006 | 2 | 1 | 3 |
| 2007 | 3 | 1 | 4 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2022 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Reverse Transcriptase Inhibitors" by people in Profiles.
-
Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy. J Antimicrob Chemother. 2024 02 01; 79(2):370-374.
-
Effect of HIV and antiretroviral therapy use on body weight changes in a cohort of U.S. veterans living with and without HIV. HIV Med. 2023 02; 24(2):180-190.
-
Infection or drug toxicity? Acute ataxia and encephalopathy after uncomplicated falciparum malaria and efavirenz dose adjustment. Malawi Med J. 2020 12; 32(4):229-231.
-
Impact of previous HIV resistance and virologic failures on virologic outcome following a switch to dolutegravir with 2 NRTIs among people living with HIV. Medicine (Baltimore). 2020 Nov 20; 99(47):e23335.
-
The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment. New Dir Child Adolesc Dev. 2020 May; 2020(171):107-133.
-
Drug resistance from preferred antiretroviral regimens for HIV infection in South Africa: A modeling study. PLoS One. 2019; 14(7):e0218649.
-
Adipocytes impair efficacy of antiretroviral therapy. Antiviral Res. 2018 06; 154:140-148.
-
CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from southern Brazil. An Acad Bras Cienc. 2017 May; 89(1 Suppl?0):497-504.
-
5-Azacytidine Enhances the Mutagenesis of HIV-1 by Reduction to 5-Aza-2'-Deoxycytidine. Antimicrob Agents Chemother. 2016 Apr; 60(4):2318-25.
-
Integrase inhibitors in late pregnancy and rapid HIV viral load reduction. Am J Obstet Gynecol. 2016 Mar; 214(3):385.e1-7.